Osman Özgür Yalın1, Tuba Gökdoğan Edgünlü2, Sevim Karakaş Çelik3, Ufuk Emre1, Taşkın Güneş4, Yüksel Erdal1, Aysun Eroğlu Ünal5. 1. Clinic of Neurology, İstanbul Training and Research Hospital, İstanbul, Turkey 2. Department of Medical Biology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey 3. Department of Molecular Biology and Genetic, Zonguldak Bülent Ecevit University Faculty of Science, Zonguldak, Turkey 4. Clinic of Neurology, İstanbul Bahçelievler State Hospital, İstanbul, Turkey 5. Department of Neurology, Tekirdağ Namık Kemal University School of Medicine, İstanbul, Turkey
Abstract
Background: It is well known that axonal degeneration plays a role in disability in patients with multiple sclerosis, and synaptopathy has recently become an important issue. Aims: To investigate the possible roles of selected synaptic and presynaptic membrane protein genetic polymorphisms (VAMP2, SNAP-25, synaptotagmin, and syntaxin 1A) in patients with multiple sclerosis. Study Design: Case-control study. Methods: A total of 123 patients with multiple sclerosis and 192 healthy controls were included. The functional polymorphisms of specific SNARE complex proteins (VAMP2, synaptotagmin XI, syntaxin 1A, and SNAP-25) were analyzed by polymerase chain reaction. Results: Significant differences were detected in the genotype and allele distribution of 26-bp Ins/Del polymorphisms of VAMP2 between patients with multiple sclerosis and control subjects; Del/Del genotype and Del allele of VAMP2 were more frequent in patients with multiple sclerosis (p=0.011 and p=0.004, respectively). Similarly, Ddel polymorphism of SNAP-25 gene C/C genotype (p=0.059), syntaxin 1A T/C and C/C genotypes (p=0.005), and synaptotagmin XI gene C allele (p=0.001) were observed more frequently in patients with multiple sclerosis. CC, syntaxin rs1569061 1A gene for 33-bp promoter region TC haplotypes, and synaptotagmin XI gene were found to be associated with an increased risk for multiple sclerosis (p=0.012). Similarly, GC haplotype for rs3746544 of SNAP-25 gene and rs1051312 of SNAP-25 gene were associated with an increased risk for multiple sclerosis (p=0.022). Conclusion: Genetic polymorphisms of SNARE complex proteins, which have critical roles in synaptic structure and communication, may play a role in the development of multiple sclerosis.
Background: It is well known that axonal degeneration plays a role in disability in patients with multiple sclerosis, and synaptopathy has recently become an important issue. Aims: To investigate the possible roles of selected synaptic and presynaptic membrane protein genetic polymorphisms (VAMP2, SNAP-25, synaptotagmin, and syntaxin 1A) in patients with multiple sclerosis. Study Design: Case-control study. Methods: A total of 123 patients with multiple sclerosis and 192 healthy controls were included. The functional polymorphisms of specific SNARE complex proteins (VAMP2, synaptotagmin XI, syntaxin 1A, and SNAP-25) were analyzed by polymerase chain reaction. Results: Significant differences were detected in the genotype and allele distribution of 26-bp Ins/Del polymorphisms of VAMP2 between patients with multiple sclerosis and control subjects; Del/Del genotype and Del allele of VAMP2 were more frequent in patients with multiple sclerosis (p=0.011 and p=0.004, respectively). Similarly, Ddel polymorphism of SNAP-25 gene C/C genotype (p=0.059), syntaxin 1A T/C and C/C genotypes (p=0.005), and synaptotagmin XI gene C allele (p=0.001) were observed more frequently in patients with multiple sclerosis. CC, syntaxin rs1569061 1A gene for 33-bp promoter region TC haplotypes, and synaptotagmin XI gene were found to be associated with an increased risk for multiple sclerosis (p=0.012). Similarly, GC haplotype for rs3746544 of SNAP-25 gene and rs1051312 of SNAP-25 gene were associated with an increased risk for multiple sclerosis (p=0.022). Conclusion: Genetic polymorphisms of SNARE complex proteins, which have critical roles in synaptic structure and communication, may play a role in the development of multiple sclerosis.
Authors: C L Barr; Y Feng; K Wigg; S Bloom; W Roberts; M Malone; R Schachar; R Tannock; J L Kennedy Journal: Mol Psychiatry Date: 2000-07 Impact factor: 15.992
Authors: N De Stefano; P M Matthews; L Fu; S Narayanan; J Stanley; G S Francis; J P Antel; D L Arnold Journal: Brain Date: 1998-08 Impact factor: 13.501
Authors: Vilte E Barakauskas; Clare L Beasley; Alasdair M Barr; Athena R Ypsilanti; Hong-Ying Li; Allen E Thornton; Hubert Wong; Gorazd Rosokilja; J John Mann; Branislav Mancevski; Zlatko Jakovski; Natasha Davceva; Boro Ilievski; Andrew J Dwork; Peter Falkai; William G Honer Journal: Neuropsychopharmacology Date: 2010-01-13 Impact factor: 7.853
Authors: D Otaegui; O Zuriarrain; T Castillo-Triviño; Am Aransay; J Ruíz-Martinez; J Olaskoaga; Jf Marti-Masso; A Lopez de Munain Journal: Mult Scler Date: 2008-08-28 Impact factor: 6.312
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Alexander Ullrich; Mathias A Böhme; Johannes Schöneberg; Harald Depner; Stephan J Sigrist; Frank Noé Journal: PLoS Comput Biol Date: 2015-09-14 Impact factor: 4.475
Authors: Benjamin D S Clarkson; Ethan Grund; Kenneth David; Renee K Johnson; Charles L Howe Journal: J Neuroinflammation Date: 2022-10-20 Impact factor: 9.587
Authors: Andrea Saul Costa; Evelyn Ferri; Franca Rosa Guerini; Paolo Dionigi Rossi; Beatrice Arosio; Mario Clerici Journal: Front Aging Neurosci Date: 2022-03-14 Impact factor: 5.750